SK284460B6 - Tvrdá želatínová kapsula obshaujúca cyklosporín - Google Patents

Tvrdá želatínová kapsula obshaujúca cyklosporín Download PDF

Info

Publication number
SK284460B6
SK284460B6 SK717-98A SK71798A SK284460B6 SK 284460 B6 SK284460 B6 SK 284460B6 SK 71798 A SK71798 A SK 71798A SK 284460 B6 SK284460 B6 SK 284460B6
Authority
SK
Slovakia
Prior art keywords
weight
cyclosporin
hard gelatin
gelatin capsule
capsule according
Prior art date
Application number
SK717-98A
Other languages
English (en)
Slovak (sk)
Other versions
SK71798A3 (en
Inventor
Klaus Neuer
Monika Petszulat
Hatto Walch
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SK71798A3 publication Critical patent/SK71798A3/sk
Publication of SK284460B6 publication Critical patent/SK284460B6/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SK717-98A 1995-11-29 1996-11-28 Tvrdá želatínová kapsula obshaujúca cyklosporín SK284460B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19544507A DE19544507B4 (de) 1995-11-29 1995-11-29 Cyclosporin enthaltende Präparate
PCT/EP1996/005279 WO1997019692A1 (fr) 1995-11-29 1996-11-28 Compositions pharmaceutiques a base de macrolides ou de cyclosporine comportant un acide gras hydroxyle, sature et polyethoxyle

Publications (2)

Publication Number Publication Date
SK71798A3 SK71798A3 (en) 1998-11-04
SK284460B6 true SK284460B6 (sk) 2005-04-01

Family

ID=7778716

Family Applications (2)

Application Number Title Priority Date Filing Date
SK267-2004A SK286613B6 (sk) 1995-11-29 1996-11-28 Farmaceutický prostriedok obsahujúci cyklosporín
SK717-98A SK284460B6 (sk) 1995-11-29 1996-11-28 Tvrdá želatínová kapsula obshaujúca cyklosporín

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SK267-2004A SK286613B6 (sk) 1995-11-29 1996-11-28 Farmaceutický prostriedok obsahujúci cyklosporín

Country Status (25)

Country Link
US (1) US6951841B2 (fr)
EP (3) EP1074263B1 (fr)
JP (2) JP3363907B2 (fr)
KR (2) KR100864618B1 (fr)
CN (2) CN1133460C (fr)
AR (1) AR012287A1 (fr)
AT (2) ATE315401T1 (fr)
AU (1) AU1139097A (fr)
BE (1) BE1010112A4 (fr)
BR (1) BR9611802A (fr)
CA (1) CA2238944A1 (fr)
CO (1) CO4761073A1 (fr)
CZ (1) CZ294260B6 (fr)
DE (4) DE19544507B4 (fr)
DK (2) DK0863765T3 (fr)
ES (2) ES2216076T3 (fr)
FR (1) FR2741537B1 (fr)
HK (1) HK1010830A1 (fr)
IT (1) IT1288395B1 (fr)
PE (1) PE22598A1 (fr)
PT (1) PT863765E (fr)
SK (2) SK286613B6 (fr)
TW (1) TW404837B (fr)
WO (1) WO1997019692A1 (fr)
ZA (1) ZA9610070B (fr)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1295658B1 (it) * 1997-09-29 1999-05-24 Menarini Ricerche Spa Composizioni farmaceutiche contenenti acido ricinoleico e loro uso per la terapia antifiammatoria ed analgesica
WO1999029316A1 (fr) 1997-12-10 1999-06-17 Severson, Mary, L. Compositions pharmaceutiques contenant une huile d'acide gras omega-3
AT408186B (de) * 1998-12-15 2001-09-25 Sanochemia Pharmazeutika Ag Wässerige zubereitung von beta-carotin
CN1167462C (zh) * 1999-03-09 2004-09-22 杭州华东医药集团生物工程研究所有限公司 一种含环孢素的药物组合物
US7919113B2 (en) 1999-12-30 2011-04-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Dispersible concentrate lipospheres for delivery of active agents
GB0003932D0 (en) * 2000-02-18 2000-04-12 Novartis Ag Pharmaceutical compositions
GB0008785D0 (en) * 2000-04-10 2000-05-31 Novartis Ag Organic compounds
AU2016206379B2 (en) * 2001-02-19 2017-09-14 Novartis Ag Cancer Treatment
AU2011226833B9 (en) * 2001-02-19 2014-07-03 Novartis Ag Cancer treatment
AU2005201004A1 (en) * 2001-02-19 2005-03-24 Novartis Ag Cancer treatment
EP3406249A1 (fr) * 2001-02-19 2018-11-28 Novartis AG Traitement de tumeurs du sein avec un dérivé de rapamycine en combinaison avec un inhibiteur de l'aromatase
GB0123400D0 (en) 2001-09-28 2001-11-21 Novartis Ag Organic compounds
JP2006521366A (ja) * 2003-03-28 2006-09-21 シグモイド・バイオテクノロジーズ・リミテッド シームレスマイクロカプセルを含む固形経口剤形
GB0307867D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Pharmaceutical composition
US20050059583A1 (en) 2003-09-15 2005-03-17 Allergan, Inc. Methods of providing therapeutic effects using cyclosporin components
US20060078616A1 (en) * 2004-08-30 2006-04-13 Georgewill Dawaye A Thermoreversible pharmaceutical formulation for anti-microbial agents comprising poloxamer polymers and hydroxy fatty acid ester of polyethylene glycol
EP1814530A2 (fr) * 2004-09-27 2007-08-08 Sigmoid Biotechnologies Limited Formules comprenant dihydropyrimidine en microcapsules
KR100866728B1 (ko) * 2004-11-12 2008-11-03 주식회사종근당 타크로리무스를 함유하는 주사제
US7297679B2 (en) 2005-07-13 2007-11-20 Allergan, Inc. Cyclosporin compositions
US7276476B2 (en) * 2005-07-13 2007-10-02 Allergan, Inc. Cyclosporin compositions
US20070015691A1 (en) 2005-07-13 2007-01-18 Allergan, Inc. Cyclosporin compositions
US20070015693A1 (en) * 2005-07-13 2007-01-18 Allergan, Inc. Cyclosporin compositions
US7288520B2 (en) 2005-07-13 2007-10-30 Allergan, Inc. Cyclosporin compositions
US7202209B2 (en) 2005-07-13 2007-04-10 Allergan, Inc. Cyclosporin compositions
US7501393B2 (en) * 2005-07-27 2009-03-10 Allergan, Inc. Pharmaceutical compositions comprising cyclosporins
US7745400B2 (en) * 2005-10-14 2010-06-29 Gregg Feinerman Prevention and treatment of ocular side effects with a cyclosporin
US9839667B2 (en) 2005-10-14 2017-12-12 Allergan, Inc. Prevention and treatment of ocular side effects with a cyclosporin
US11975161B2 (en) 2006-11-20 2024-05-07 Lutonix, Inc. Drug releasing coatings for balloon catheters
JP2010523554A (ja) 2007-04-04 2010-07-15 シグモイド・ファーマ・リミテッド タクロリムスの医薬組成物
ES2963291T3 (es) 2007-04-26 2024-03-26 Sublimity Therapeutics Ltd Fabricación de múltiples minicápsulas
US9994585B2 (en) * 2007-12-31 2018-06-12 Aphios Corporation Transplantation therapies
WO2010029374A1 (fr) * 2008-09-12 2010-03-18 Critical Pharmaceuticals Limited Améliorations apportées à l’absorption d’agents thérapeutiques à travers des membranes de muqueuses ou à travers la peau
CN101502641B (zh) * 2009-02-23 2012-05-02 姚定全 一种注射给药的环孢素药物组合物
EP2471518B1 (fr) 2009-05-18 2017-08-23 Sigmoid Pharma Limited Composition comprenant des gouttes d'huile
US9878036B2 (en) 2009-08-12 2018-01-30 Sigmoid Pharma Limited Immunomodulatory compositions comprising a polymer matrix and an oil phase
RU2012145021A (ru) * 2010-03-25 2014-04-27 Лутоникс, Инк. Покрытия, высвобождающие лекарственные средства, для медицинских устройств
GB201020032D0 (en) 2010-11-25 2011-01-12 Sigmoid Pharma Ltd Composition
GB201212010D0 (en) 2012-07-05 2012-08-22 Sigmoid Pharma Ltd Formulations
GB201319791D0 (en) 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
WO2016071515A1 (fr) 2014-11-07 2016-05-12 Sigmoid Pharma Limited Compositions comprenant de la cyclosporine
CN106166296A (zh) * 2016-07-01 2016-11-30 江南大学 一种辅助雷帕霉素治疗多种肿瘤的药物组合物
JP6880136B2 (ja) * 2019-09-27 2021-06-02 ルトニックス，インコーポレーテッド 医療用具のための薬物放出コーティング

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1274354A (fr) 1956-03-10 1961-10-27 Agents tensio-actifs obtenus à partir de triglycérides et polyéthylène glycol
GB1171125A (en) 1966-06-08 1969-11-19 Glaxo Lab Ltd Improvements in or relating to Injectable Preparations
US3813345A (en) 1971-08-05 1974-05-28 Vanguard Chem Co Inc Method of producing microcolloidal aqueous emulsions of unsaturated organic compounds
US3954967A (en) 1971-08-05 1976-05-04 Vanguard Chemical Company, Inc. Method of producing microcolloidal aqueous emulsions of unsaturated organic insecticidal compounds
US4073943A (en) 1974-09-11 1978-02-14 Apoteksvarucentralen Vitrum Ab Method of enhancing the administration of pharmalogically active agents
US4146499A (en) 1976-09-18 1979-03-27 Rosano Henri L Method for preparing microemulsions
JPS53107408A (en) 1977-02-28 1978-09-19 Yamanouchi Pharmaceut Co Ltd Micellar preparation for rectal infusion
FI65914C (fi) 1978-03-07 1984-08-10 Sandoz Ag Foerfarande foer framstaellning av farmaceutiska kompositionerinnehaollande cyklosporin a
CH641356A5 (en) 1979-02-27 1984-02-29 Sandoz Ag Pharmaceutical compositions containing cyclosporin
FR2502951B1 (fr) 1981-04-06 1985-12-06 Sandoz Sa Compositions pharmaceutiques topiques sous forme d'une micro-emulsion
AU558155B2 (en) 1982-02-01 1987-01-22 Sandoz Ltd. Treating multiple sclerosis with dihydro-cyclosporin d
DE3225706C2 (de) 1982-07-09 1984-04-26 A. Nattermann & Cie GmbH, 5000 Köln Flüssige Wirkstofformulierungen in Form von Konzentraten für Mikroemulsionen
DE3235612A1 (de) 1982-09-25 1984-03-29 Bayer Ag, 5090 Leverkusen Mikroemulsionen
DE3237814A1 (de) 1982-10-12 1984-04-12 Warner-Lambert Co., 07950 Morris Plains, N.J. Wasserfreie emulsionen und verwendung derselben
DE3316805A1 (de) 1983-05-07 1984-11-08 Robert Bosch Gmbh, 7000 Stuttgart Hoer- oder fernsehrundfunksignalempfaenger
JPS6024776A (ja) 1983-07-19 1985-02-07 Fujitsu Ltd 中間調画像圧縮方式
JPS6061535A (ja) 1983-08-24 1985-04-09 エフ・ホフマン・ラ・ロシユ・ウント・コンパニ−・アクチエンゲゼルシヤフト 製薬学的組成物
FR2553661B1 (fr) 1983-10-19 1985-12-20 Rhone Poulenc Sante Nouvelles microemulsions pharmaceutiquement acceptables
DE3406497A1 (de) 1984-02-23 1985-09-05 Mueller Bernhard Willi Werner Hochdisperse pharmazeutische mehrkomponentensysteme und verfahren zu ihrer herstellung
US4963367A (en) 1984-04-27 1990-10-16 Medaphore, Inc. Drug delivery compositions and methods
US4794000A (en) 1987-01-08 1988-12-27 Synthetic Blood Corporation Coacervate-based oral delivery system for medically useful compositions
GB8903804D0 (en) 1989-02-20 1989-04-05 Sandoz Ltd Improvements in or relating to organic compounds
US5639724A (en) 1984-07-24 1997-06-17 Sandoz Ltd. Cyclosporin galenic forms
DE3580717D1 (de) 1984-08-02 1991-01-10 Sandoz Ag Pharmazeutische anwendung von (nva)2-cyclosporine.
CH662944A5 (it) 1984-10-18 1987-11-13 Pier Luigi Prof Dr Luisi Procedimento per la preparazione di biocompatibili di micelle inverse di biocompatibili e loro utilizzazione.
JPS61280435A (ja) 1985-04-04 1986-12-11 Kanji Takada サイクロスポリン類のリンパ指向性製剤
JPS61249918A (ja) 1985-04-26 1986-11-07 Yutaka Mizushima 点眼剤
IL78929A0 (en) 1985-07-29 1986-09-30 Abbott Lab Microemulsion compositions for parenteral administration
US5023271A (en) 1985-08-13 1991-06-11 California Biotechnology Inc. Pharmaceutical microemulsions
US4797272A (en) 1985-11-15 1989-01-10 Eli Lilly And Company Water-in-oil microemulsions for cosmetic uses
SE457693B (sv) 1986-07-01 1989-01-23 Drilletten Ab Komposition med reglerad frigoering vari ett biologiskt material aer loest eller dispergerat i en l2-fas
DE3629386A1 (de) 1986-08-29 1988-03-03 Scherer Gmbh R P Gelatinekapseln und verfahren zu ihrer herstellung
DE3630279A1 (de) 1986-09-05 1988-03-17 Basf Ag Verfahren zur uebertragung von farbstoffen
DE3707711A1 (de) 1987-03-11 1988-09-22 Hoechst Ag Oel-in-wasser-emulsionen, verfahren zu deren herstellung und deren verwendung
CA1301642C (fr) 1987-03-30 1992-05-26 Howard Bernard Dawson Formulations chimiques
US4798823A (en) 1987-06-03 1989-01-17 Merck & Co., Inc. New cyclosporin analogs with modified "C-9 amino acids"
ES2059558T3 (es) 1987-06-17 1994-11-16 Sandoz Ag Ciclosporins y su uso como productos farmaceuticos.
GB2206119B (en) 1987-06-22 1990-10-31 Merck & Co Inc A new cyclosporin derivative with modified "8-amino acid"
US4835002A (en) 1987-07-10 1989-05-30 Wolf Peter A Microemulsions of oil in water and alcohol
HU205010B (en) 1987-09-15 1992-03-30 Sandoz Ag Process for producing pharmaceutical compositions comprising compounds soluble up to 1 per cent and having medical activity
US5756450A (en) 1987-09-15 1998-05-26 Novartis Corporation Water soluble monoesters as solubilisers for pharmacologically active compounds and pharmaceutical excipients and novel cyclosporin galenic forms
IL88076A (en) 1987-10-28 1993-01-14 Nippon Shinyaku Co Ltd Fat emulsions as drug carriers
US4914188A (en) 1987-11-16 1990-04-03 Merck & Co., Inc. Novel 6-position cyclosporin analogs as non-immunosuppressive antagonists of cyclosporin binding to cyclophilin
HU203564B (en) 1987-12-21 1991-08-28 Sandoz Ag Process for producing new orthorombos cyclosporin without solvatation
AU609242B2 (en) 1988-01-29 1991-04-26 Novartis Ag Cyclosporin compositions
CH679119A5 (fr) 1988-05-13 1991-12-31 Sandoz Ag
HU201567B (en) * 1988-07-21 1990-11-28 Gyogyszerkutato Intezet Process for production of intravenous medical compositions containing cyclosphorin
GB2222770B (en) 1988-09-16 1992-07-29 Sandoz Ltd Pharmaceutical compositions containing cyclosporins
US5342625A (en) * 1988-09-16 1994-08-30 Sandoz Ltd. Pharmaceutical compositions comprising cyclosporins
EP0361928B1 (fr) 1988-09-29 1994-04-27 Shiseido Company Limited Composition émulsifiée
GB8825541D0 (en) 1988-11-01 1988-12-07 Fisons Plc Formulation
WO1990008537A1 (fr) 1989-02-06 1990-08-09 Abbott Laboratories Compositions pharmaceutiques administrees oralement
GB2230440B (en) 1989-02-09 1993-05-19 Sandoz Ltd Novel cyclosporin galenic forms
US4996193A (en) 1989-03-03 1991-02-26 The Regents Of The University Of California Combined topical and systemic method of administration of cyclosporine
US5177110A (en) 1989-10-27 1993-01-05 Ciba-Geigy Corporation Injectable parasiticidal composition
HU207222B (en) * 1990-02-15 1993-03-29 Chinoin Gyogyszer Es Vegyeszet Process for producing eyedrops containing primycin
US5260301A (en) * 1990-03-01 1993-11-09 Fujisawa Pharmaceutical Co., Ltd. Pharmaceutical solution containing FK-506
GB9113872D0 (en) * 1991-06-27 1991-08-14 Sandoz Ag Improvements in or relating to organic compounds
US5206219A (en) 1991-11-25 1993-04-27 Applied Analytical Industries, Inc. Oral compositions of proteinaceous medicaments
GB9208712D0 (en) 1992-04-22 1992-06-10 Sandoz Ltd Pharmaceutical compositions containing cyclosporin derivates
DK0589843T3 (da) * 1992-09-25 2002-04-02 Novartis Ag Cyclosporinholdige farmaceutiske præparater
CH686761A5 (de) * 1993-05-27 1996-06-28 Sandoz Ag Galenische Formulierungen.
DE4322826A1 (de) * 1993-07-08 1995-01-12 Galenik Labor Freiburg Gmbh Pharmazeutisches Präparat
KR0146671B1 (ko) * 1994-02-25 1998-08-17 김충환 사이클로스포린-함유 분말 조성물
ATE188870T1 (de) 1994-10-04 2000-02-15 Lohmann Rudolf Lomapharm Lösungen von anthrachinonen zur parenteralen applikation
CA2231404C (fr) * 1994-11-03 2009-02-17 Arzneimittelwerk Dresden Gmbh Nouvelles formes de preparations de cycylosporines pour administration par voie orale, de composition simple et haute biodisponibilite, et leur procede de production

Also Published As

Publication number Publication date
TW404837B (en) 2000-09-11
DE69635720T2 (de) 2006-08-10
DE19549852B4 (de) 2009-06-04
KR20040094679A (ko) 2004-11-10
CN1204261A (zh) 1999-01-06
EP1604650A3 (fr) 2008-04-02
HK1010830A1 (en) 1999-07-02
AU1139097A (en) 1997-06-19
FR2741537A1 (fr) 1997-05-30
EP1074263A3 (fr) 2001-04-11
JP2002338492A (ja) 2002-11-27
PT863765E (pt) 2004-06-30
JP3831676B2 (ja) 2006-10-11
US6951841B2 (en) 2005-10-04
CN1496742A (zh) 2004-05-19
EP0863765B1 (fr) 2004-02-18
CN1246035C (zh) 2006-03-22
JP3363907B2 (ja) 2003-01-08
KR100864618B1 (ko) 2008-10-22
WO1997019692A1 (fr) 1997-06-05
CO4761073A1 (es) 1999-04-27
KR100593701B1 (ko) 2007-04-25
DE19544507B4 (de) 2007-11-15
DE69631601D1 (de) 2004-03-25
EP1074263B1 (fr) 2006-01-11
ES2254091T3 (es) 2006-06-16
BE1010112A4 (fr) 1997-12-02
ITRM960810A0 (it) 1996-11-27
DK1074263T3 (da) 2006-03-06
CZ163198A3 (cs) 1998-08-12
CN1133460C (zh) 2004-01-07
IT1288395B1 (it) 1998-09-22
ES2216076T3 (es) 2004-10-16
DE69635720D1 (de) 2006-04-06
ZA9610070B (en) 1998-05-29
PE22598A1 (es) 1998-05-11
ATE259649T1 (de) 2004-03-15
DK0863765T3 (da) 2004-06-01
BR9611802A (pt) 1999-09-21
CZ294260B6 (cs) 2004-11-10
FR2741537B1 (fr) 2000-10-13
CA2238944A1 (fr) 1997-06-05
EP1074263A2 (fr) 2001-02-07
JPH11511484A (ja) 1999-10-05
AR012287A1 (es) 2000-10-18
EP1604650A2 (fr) 2005-12-14
EP0863765A1 (fr) 1998-09-16
DE69631601T2 (de) 2004-12-16
DE19544507A1 (de) 1997-06-05
KR19990071581A (ko) 1999-09-27
ITRM960810A1 (it) 1998-05-27
SK71798A3 (en) 1998-11-04
ATE315401T1 (de) 2006-02-15
SK286613B6 (sk) 2009-02-05
US20010003589A1 (en) 2001-06-14

Similar Documents

Publication Publication Date Title
SK284460B6 (sk) Tvrdá želatínová kapsula obshaujúca cyklosporín
KR100452004B1 (ko) 경구투여용라파마이신제형
TWI510238B (zh) 穩定化他克莫司（ｔａｃｒｏｌｉｍｕｓ）組合物
SK286178B6 (sk) Farmaceutická kompozícia obsahujúca makrolid a kyselinu, spôsob stabilizácie makrolidu proti degradácii a použitie kyseliny na jeho stabilizáciu
KR19990028942A (ko) 제약 조성물
JPH0611703B2 (ja) 新規シクロスポリン製剤
JPH07196518A (ja) 経口投与用ラパマイシン製剤
KR100513919B1 (ko) 경구투여용라파마이신고체제형및이의제조방법
JPH07149656A (ja) 経口投与ラパマイシン製剤
US20090011013A1 (en) Tacrolimus Combination Products
RU2184541C2 (ru) Препараты рапамицина для орального применения
KR0173349B1 (ko) 사이클로스포린-함유 고체 분산체 조성물
US20230101012A1 (en) Stabilized tacrolimus composition

Legal Events

Date Code Title Description
MM4A Patent lapsed due to non-payment of maintenance fees

Effective date: 20091128